Table 2. Demographic and clinical features of the AML and normal subjects.
Training Set | Validation Set | Training Set | Validation Set | |||||||
Variable | Norm | AML | Norm | AML | Variable | Norm | AML | Norm | AML | |
Age (mean±SD) | 47.18±15.24 | 51.42±16.31 | 51.45±17.54 | 47.90±15.23 | CD2 | |||||
<47 | 18 | 28 | 56 | 48 | Negative | 28 | 81 | |||
≥47 | 22 | 17 | 39 | 47 | Positive | 17 | 14 | |||
Gender | CD5 | |||||||||
Male | 20 | 24 | 45 | 58 | Negative | 41 | 90 | |||
Female | 20 | 21 | 40 | 37 | Positive | 4 | 5 | |||
Hemoglobin | CD7 | |||||||||
Male | Negative | 28 | 79 | |||||||
<120 | 0 | 24 | 0 | 53 | Positive | 17 | 16 | |||
≥120 | 20 | 0 | 45 | 5 | CD10 | |||||
Female | Negative | 45 | 91 | |||||||
<110 | 0 | 21 | 0 | 35 | Positive | 0 | 4 | |||
≥110 | 20 | 1 | 40 | 2 | CD13 | |||||
White blood cell | Negative | 1 | 6 | |||||||
<4.0 | 0 | 17 | 0 | 40 | Positive | 44 | 89 | |||
4.0–10.0 | 40 | 6 | 95 | 14 | CD14 | |||||
>10.0 | 0 | 22 | 0 | 41 | Negative | 30 | 65 | |||
Platelet | Positive | 15 | 30 | |||||||
<100 | 0 | 44 | 0 | 85 | CD19 | |||||
100–300 | 38 | 1 | 95 | 8 | Negative | 35 | 78 | |||
>300 | 2 | 0 | 0 | 2 | Positive | 10 | 17 | |||
FAB Classification | CD22 | |||||||||
M1 | 5 | 14 | Negative | 39 | 87 | |||||
M2 | 13 | 33 | Positive | 6 | 8 | |||||
M3 | 8 | 9 | CD33 | |||||||
M4 | 8 | 10 | Negative | 0 | 5 | |||||
M5 | 11 | 29 | Positive | 45 | 90 | |||||
LDH | CD34 | |||||||||
≤245 | 17 | 39 | Negative | 14 | 30 | |||||
>245 | 28 | 56 | Positive | 31 | 65 |